Mangromicins, six new anti-oxidative agents isolated from a culture broth of the actinomycete, *Lechevalieria aerocolonigenes* K10-0216

Takuji Nakashima¹, Yoshiyuki Kamiya², Masato Iwatsuki^{2,3}, Yōko Takahashi^{2,3} and Satoshi Ōmura³

We have been continually searching for novel chemical compounds from culture broths of various actinomycetes using a physicochemical screening system. During the course of this program, we have previously reported the discovery of two new natural products, designated mangromicins A and B, discovered in a broth of a rare actinomycete strain, *Lechevalieria aerocolonigenes* K10-0216. Mangromicins have a unique and rare structure, a cyclopentadecane skeleton with a tetrahydrofuran unit and a 5,6-dihydro-4-hydroxy-2-pyrone moiety. New mangromicins A and B, were isolated by using an improved production medium. As a consequence, six analogs, together with mangromicins A and B, were isolated from a cultured broth of *L. aerocolonigenes* K10-0216. We named them mangromicins D, E, F, G, H and I. All mangromicins showed radical scavenging activities against 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radicals and nitric oxide generated from LPS-stimulated RAW264.7 cells, a murine macrophage cell line. Among the analogs, mangromicins A and I showed the most potent DPPH radical scavenging activity and nitric oxide scavenging activity, respectively. *The Journal of Antibiotics* (2014) **67**, 533–539; doi:10.1038/ia.2014.34; published online 2 April 2014

Keywords: actinomycete strain; Lechevalieria aerocolonigenes; Mangromicins; radical scavenging activity

INTRODUCTION

Of the 1073 small molecule organic compounds introduced worldwide as drugs during the period 1981–2010, 66% were natural products, derivatives or mimics of natural products.¹ Natural products from microbial cultured broths have been screened by bioassay programs to identify useful bioactivity properties.² Many bioactive compounds have been discovered by this approach, such as kanamycin,³ leucomycin⁴ and avermectin,⁵ all well-known useful compounds of microbial metabolite origin. However, the search for new compounds from microorganisms is often criticized for resulting in the re-discovery, re-isolation and re-characterization of previously known compounds. Therefore, it is important to avoid this duplication as early as possible in the process.

We have discovered new natural products, trehangelins⁶ and mangromicins,⁷ from culture broths of microorganisms using physicochemical (PC) screening. As PC screening is a method utilizing the PC properties of compounds, such as polarity, molecular formula and UV spectra, this screening method does not depend on biological activity. The search for new compounds via this screening system is guided by liquid chromatography-UV detection (LC/UV), liquid chromatography-MS (LC/MS), and color reaction (for example, detection of alkaloids by Dragendorff's reagent).

We constructed an in-house database based on the PC data of various known compounds in microbial culture broths. Using this database and external databases, such as the Dictionary of Natural Products (http://dnp.chemnetbase.com/), a cultured broth that was predicted to contain new compounds was selected. The structure elucidation of new compounds that were isolated from the cultured broth was carried out. Subsequently, the purified new compound was investigated for biological activities (antimicrobial, antitumor, antiparasitic activities, etc.) by specific customized bioassays.

PC screening system has already identified several new natural compounds, for example, staurosporine,⁸ dityromycin⁹ and trehangelins.⁶ Mangromicins A (1) and B (2) were also discovered from a cultured broth of the actinomycete species, *Lechevalieria aerocolonigenes* K10-0216, isolated from mangroves in Iriomote Island, Okinawa prefecture, Japan (Figure 1).^{7,10,11} Mangromicins have a unique cyclopentadecane skeleton with a tetrahydrofurane unit and a 5,6-dihydro-4-hydroxy-2-pyrone moiety. Moreover, we discovered six new analogs (mangromicins D–I (**3–8**)) from a broth of same strain K10-0216 using an improved production medium.¹² In this study, we report the fermentation, isolation, structure elucidation and anti-oxidative activities of these mangromicin analogs.

E-mail: takuji@lisci.kitasato-u.ac.jp or ytakaha@lisci.kitasato-u.ac.jp

¹Research Organization for Infection Control Sciences, Kitasato University, Tokyo, Japan; ²Graduate School of Infection Control Sciences, Kitasato University, Tokyo, Japan and ³Kitasato Institute for Life Sciences, Kitasato University, Tokyo, Japan

Correspondence: Dr T Nakashima, Research Organization for Infection Control Sciences, Kitasato University and Yōko Takahashi, Kitasato Institute for Life Sciences, Kitasato University, 5-9-1 Shirokane, Minato-ku, Tokyo 108-8641, Japan.

Received 19 December 2013; revised 20 February 2013; accepted 9 March 2014; published online 2 April 2014

534

RESULTS AND DISCUSSION

Improvement of fermentation

We previously reported that mangromicins A (1) and B (2) were isolated from the cultured broth of L. aerocolonigenes K10-0216 using a production medium consisting of 2% soluble starch, 0.5% glycerol, 1.0% de-fatted wheat germ, 0.3% meat extract, 0.3% dry yeast and 0.3% CaCO₃ (basal medium). However, the yields of both 1 and 2 were $0.24 \,\mu g \,\mathrm{ml}^{-1}$ in the basal medium (Supplementary Figure S1). Therefore, we improved the production medium to increase the productivity of both 1 and 2. The productivity of 1 and 2 were examined by altering the amount of all components in the basal medium. The composition of the modified medium was fixed at 5% soluble starch, 0.5% glycerol, 1.0% de-fatted wheat germ, 1.0% dry yeast and 0.3% CaCO₃. The productivity of 1 and 2 in the modified medium was increased 100-fold compared with the original medium (Supplementary Figure S1). In addition, many new analogs were detected by LC/UV and LC/MS which were subsequently isolated and their chemical structures were elucidated.

Isolation of six new mangromicin analogs

The procedure for isolation of 1–8 is summarized in Scheme 1. Isolation of all mangromicin analogs was guided by PC properties using LC/UV and LC/MS equipment. The above-described modified medium was used for production of mangromicin analogs. The 8-day-old culture broth (101) was centrifuged to separate mycelium





Mangromicin B (2)



and supernatant. The supernatant was extracted three times with ethyl acetate (101). The organic layer was concentrated to dryness in vacuo to afford a crude material (6 g). The ethyl acetate extract was applied to silica gel column chromatography FL100D (60 i.d. \times 200 mm, Fuji Silysia Co., Tokyo, Japan), which was eluted with each 11 of a mixture of CHCl₃-MeOH (100:0, 100:1, 50:1 and 10:1) in that order. The CHCl₃-MeOH (100:0) fraction (138 mg) was dissolved in a small amount of MeOH and purified by HPLC on an Inertsil ODS-4 column (10 i.d. \times 250 mm) with 40% MeCN at 4.7 ml min⁻¹ (monitoring at UV 254 nm). The vield of mangromicin E (4) was 11 mg. The CHCl₃-MeOH (100:1) fraction (550 mg) was applied on an ODS column (40 i.d. × 150 mm, Senshu Scientific Co., Tokyo, Japan). After washing with 40% MeOH, the fractions containing mangromicins H (7) and I (8) were eluted with 50% MeOH, followed by concentration in vacuo. This fraction (178 mg) was dissolved in a small amount of MeOH and purified by HPLC on an Inertsil ODS-4 column (10 i.d. \times 250 mm) with 40% MeOH at 4.7 ml min⁻¹ (monitoring at UV 254 nm). The yields of mangromicins H (7) and I (8) were 20 and 0.8 mg, respectively. The same ODS-treated fraction containing mangromicin B (2) was eluted with 60% MeOH, followed by concentration in vacuo. Next, the same ODS-treated fractions containing mangromicin B (2) was eluted with 60% MeOH, followed by concentration in vacuo. This fraction (278 mg) was dissolved in a small amount of MeOH and purified by HPLC on an Inertsil ODS-4 column (10 i.d. × 250 mm) with 40% MeOH at 4.7 ml min⁻¹ (monitoring at UV 254 nm). The yield of mangromicin B (2) was 20 mg. The CHCl₃-MeOH (50:1) fraction (510 mg) was applied on an ODS column (40 i.d. × 150 mm, Senshu Scientific Co.). After washing with 40% MeOH, the fractions containing mangromicins A (1) and D (3) were eluted with 50% MeOH, and then concentrated in vacuo. This fraction (211 mg) was dissolved in a small amount of MeOH and purified by HPLC on an Inertsil ODS-4 column (10 i.d. \times 250 mm) with 15% MeOH at 4.7 ml min⁻¹ (monitoring at UV 254 nm). The yields of mangromicins A (1) and D (3) were 35 and 60 mg, respectively. The CHCl₃-MeOH (10:1) fraction (650 mg) was applied on an ODS column (40 i.d. \times

150 mm). After washing with 40% MeOH, the fractions containing



**ODS open column (40 i.d. × 150 mm) eluted with MeOH/H₂O or CH₂CN/H₂O system

Scheme 1 Purification of mangromicin analogs.

mangromicins F (5) and G (6) were eluted with 50% MeOH, followed concentration *in vacuo*. This fraction (190 mg) was dissolved in a small amount of MeOH and purified by HPLC on an Inertsil ODS-4 column (10 i.d. \times 250 mm) with 15% MeOH at 4.7 ml min⁻¹ (monitoring at UV 254 nm). The yields of mangromicins F (5) and G (6) were 20 and 9 mg, respectively.

PC properties of six new mangromicin analogs

The PC properties of compounds **3–8** are summarized in Table 1. All analogs are readily soluble in MeOH, EtOH and MeCN. Compounds **3–8** showed absorption maxima at 231–251 nm in UV spectra. The IR absorption at 3421–3451 and 1651–1655 cm⁻¹ in **3–8** suggested the presence of hydroxyl and carbonyl groups. The PC properties are similar for not only these six compounds but also for mangromicins A (1) and B (2), confirming that these compounds are structurally related.

Structure elucidation of mangromicin H (7)

Structure analysis was initially performed using mangromicin H (7) as it had the lowest MW among the analogs. Mangromicin H (7) was obtained as a pale yellow powder determined to have the molecular formula of $C_{21}H_{32}O_6$ by HRESIMS $[M+H]^+$ *m/z* 381.2277 (calcd for $C_{21}H_{33}O_6$, 381.2272). The 1D and 2D NMR spectra of 7 were measured in CD₃OD.

The ¹H and ¹³C NMR spectral data of 7 are listed in Tables 2 and 3, respectively. The ¹H NMR data indicated the presence of three oxygenated sp^3 methines, three sp^3 methines containing two methines coupled to methyl groups, six methylenes, one primary methyl, two secondary methyls and one tertiary methyl. The ¹³C NMR spectrum showed the resonances of 21 carbons, which were classified into two olefinic carbons (δ_c 102.8 and 169.3), two carbonyl carbons (δ_c 169.6 and 212.8), one oxygenated sp^3 quaternary carbon (δ_c 83.8), three oxygenated sp³ methine carbons (δ_c 73.7, 69.2 and 82.0), three sp³ methine carbons (δ_c 46.1, 49.3 and 37.0), six sp³ methylene carbons $(\delta_{c}$ 44.3, 37.7, 49.4, 36.5, 19.5 and 25.8) and four methyl carbons $(\delta_c 11.9, 15.5, 15.5 \text{ and } 25.3)$ by HSQC spectra. The ¹H–¹H COSY and HOHAHA spectra revealed four partial structures: (a) C-5/C-6, (b) C-8/C-13, C-8/C-8-Me and C-12/C-12-Me, (c) C-15/C-16, (d) C-4/C-2'-Me, as shown in Figure 2. The presence of a 5,6dihydro-4-hydroxy-2-pyrone moiety was confirmed by the HMBC correlations from H₃-2'-Me to C-4; from H₂-1' to C-3, C-4 and C-5;

Table 1 PC properties of mangromicin analogs

from H-4 to C-1' and C-2'-Me; from H-5 to C-3, C-4, C-6 and C-1'; from H-16 to C-1, C-2 and C-3. A tetrahydrofurane unit with a secondary methyl and a tertiary methyl linked to C-12 and C-14 positions was confirmed by the HMBC correlations from H-12 to C-14; from H₂-13 to C-11; from H₃-12-Me to C-11, C-12 and C-13; from H₃-14-Me to C-13 and C-14. The HMBC correlations from H₃-14-Me to C-15; from H₂-15 to C-14, C-14-Me and C-16; from H₂-16 to C-14, and C-15 showed that a 5,6-dihydro-4-hydroxy-2pyrone moiety and tetrahydrofurane unit were connected by an ethylene bond. Finally, the HMBC correlations from H-6 to C-5 and C-7; from H₃-8-Me to C-7 revealed the connectivity between C-6 and C-8 via ketone carbon at C-7, which connected two partial structures a and b. Therefore, the planar structure of 7 was elucidated as shown in Figure 2a, and it was designated as mangromicin H, 4-de-*n*-propyl-4-ethyl-9-dehydroxy analog of mangromicin A (1).

The relative configuration of 7 was estimated by ¹H-¹H coupling constant analysis and ROESY experiments (Figure 2b). The ROESY correlations were observed between H2-13b/H3-12-Me and H2-13b/ H₃-14-Me. These results indicated that H₃-14-Me and H₃-12-Me are located on the identical surface of the tetrahydrofurane unit. Moreover, the ROESY correlations were observed between H₃-8-Me/H-10 and H-10/H₃-12-Me. In addition, J-coupling between H_{α 1} and H_{β 1} was almost zero, and between $H_{\alpha 2}$ and $H_{\beta 2}$ was a small coupling constant (0.8 Hz). Therefore, the relative configuration from C-8 to C-14 in 7 was determined as shown in Figure 2b. ROESY and NOE correlations were observed between H-4 and H-6a and between H-4 and H-5. No coupling constants were observed between H-4/H-5 and H-5/H-6a. These results reveal that the n-ethyl group at C-4 and methylene at C-6 bound to 5,6-dihydro-4-hydroxy-2-pyrone moiety are located on the opposite surface. Therefore, it was suggested that 7 has the relative configuration of 4R*, 5R*, 8R*, 9S*, 10R*, 11R*, 12S* and 14S* (Figure 2b).

Structure elucidation of mangromicin D (3)

Mangromicin D (**3**) was obtained as a pale yellow powder determined to have the molecular formula of $C_{22}H_{34}O_7$ by HRESIMS $[M + H]^+$ m/z 411.2383 (calcd for $C_{22}H_{35}O_7$, 411.2392). As some broadened signals were observed in CD₃OD, the 1D and 2D spectra of **3** in DMSO(dimethylsulphoxide)- d_6 were also measured at 80 °C to yield sharper signals.

	Mangromicin					
	D (3)	E (4)	F (5)	G (6)	H (7)	l (8)
Appearance	Pale yellow					
Molecular formula	C ₂₂ H ₃₄ O ₇	C ₂₂ H ₃₂ O ₆	C ₂₁ H ₃₂ O ₇	C ₂₂ H ₃₄ O ₇	C ₂₁ H ₃₂ O ₆	C ₂₂ H ₃₂ O ₇
MW	410.5012	392.4859	396.4746	410.5012	380.4752	408.4853
ESI-MS(m/z)						
Calcd	411.2392	393.2277	397.2218	411.2375	381.2272	409.2222
Found	411.2383	393.2277	397.2226	411.2385	381.2277	409.2226
[α] _D ^{25.3} (<i>c</i> 0.1, MeOH)	+27.96	+ 30.48	+51.56	+ 29.16	+ 33.80	NT
UV λ_{max}^{MeOH} nm (ε)	251 (1806)	231 (314)	250 (1387)	251 (1231)	251 (1521)	246 (490)
IR v _{max} ^{KBr} cm ⁻¹	3421, 1655	3451, 1651	3433, 1651	3425, 1651	3430, 1651	3431, 1651
Soluble in	MeOH	MeOH	MeOH	MeOH	MeOH	MeOH
	EtOH MeCN					

Abbreviation: NT, not tested.

Mangromicins,	new	anti-oxidative	age	nts
		T Nakashim	a et	al

analogs

Table 2 ¹	H NMR	data for	mangromicin
----------------------	-------	----------	-------------

Position	D (3) ^a	E (4) ^b	F (5) ^b	G (6) ^b	Н (7) ^ь	I (8) ^b
	δ _H , mult (J in Hz)	δ _H , mult (J in Hz)	δ _H , mult (J in Hz)			
2		4.63 dd (2.0, 9.6)				
4	2.12 t (7.2)	2.83 ddd (6.0, 6.0, 8.4)	2.05 m	2.13 m	2.01 dd (2.4, 4.0)	2.05 dt (4.0, 14.8)
5	4.56 d (8.4)	4.94 ddd (6.0, 12.0, 12.6)	4.83 m	4.73 dd (1.6, 11.8)	4.79 d (12.0)	4.93 dd (0.8, 11.2)
6a	2.33 m	2.51 m	2.38 m	2.15 dd (17.4, 1.6)	2.36 d (18.4)	2.40 m
6b	4.16 dd (8.4, 16.4)	3.71 t (12.6)	4.34 dd (11.6, 18.4)	4.46 dd (17.4, 11.8)	4.48 dd (12.0, 18.4)	4.78 dd (11.2, 18.4)
8	2.96 m		3.33 m	2.72 m	2.72 m	
9a	1.68 m	6.67 d (8.8)	1.61 m	1.90 m	1.76 m	4.20 d (8.4)
9b	1.84 m		1.80 m	2.32 m	2.42 m	
10	3.50 m	4.70 d (8.8)	3.65 m	3.58 ddd (10.4, 3.6, 0.4)	3.57 ddd (0.8, 3.2, 5.6)	3.20 d (8.4)
11	3.38 dd (2.0, 7.2)	3.60 m	3.55 m	3.33 m	3.40 m	3.42 d (8.8)
12	2.30 m	2.42 m	2.44 m	2.60 m	2.44 dt (3.2, 11.4)	2.55 m
13a	1.54 m	1.45 dd (8.4, 12.6)	1.59 dd (2.0, 5.2)	1.44 m	1.64 m	1.63 m
13b	1.64 dd (8.7, 8.7)	2.10 dd (8.4, 12.6)	1.72 m	2.15 m	1.70 m	1.85 dd (11.6, 13.2)
15a	1.18 dt (2.0, 9.8)	1.28 m	1.26 dt (3.6, 14.2)	1.37 m	1.25 dt (4.0, 14.4)	1.27 dt (4.0, 14.6)
15b	2.38 m	2.56 m	2.49 ddd (4.0, 13.6, 14.2)	2.56 m	2.48 m	2.38 m
16a	1.93 dd (4.8, 9.8)	1.67 m	2.06 m	2.05 dt (4.0, 7.2)	2.04 m	2.11 m
16b	2.71 m	2.45 m	2.85 ddd (4.4, 13.6, 15.4)	2.73 m	2.88 ddd (4.0, 10.4, 12.0)	2.90 ddd (3.8, 13.2, 14.6)
1′	1.48 s	1.32 m, 1.97 m	1.65 m	1.61 m, 1.57 m	1.64 m, 1.70 m	1.68 m, 1.72 m
2′	1.30 m, 1.44 m	1.38 m, 1.48 m		1.38 m, 1.53 m		
2'-(Me)			1.03 t (7.4)		1.03 t (8.0)	1.05 t (7.6)
3'-(Me)	0.88 t (6.4)	0.98 t (7.2)		0.96 t (12.8)		
8-CH ₂	3.30 m, 3.50 m		3.52 m, 3.67 m			5.68 d (2.0), 6.48 d (2.0)
8-Me 9-OMe		1.79 d (1.2)		1.03 (3H, d, 13.7)	1.06 d (5.6)	3.24 s
12-Me 14-CH ₂	1.0 d (7.0)	1.20 d (7.6)	1.07 d (6.8)	1.09 d (13.7) 3.47 d (10.8), 3.96 d (10.8)	1.05 d (3.6)	1.06 d (6.8)
14-Me	1.26 s	1.42s	1.35s		1.34 s	1.38s

^aIn DMSO-*d*₆ (80 °C).

^bIn CH₃OD.

From a comparison of the ¹H and ¹³C NMR of 3 and 7, the signals of a *n*-propyl (1'; $\delta_{\rm H}$ 1.48/ $\delta_{\rm C}$ 32.9, 2'; $\delta_{\rm H}$ 1.30 and 1.44/ $\delta_{\rm C}$ 19.1, 3'; $\delta_{\rm H}$ 0.88/ $\delta_{\rm C}$ 13.3) and hydroxymethyl (8-CH₂; $\delta_{\rm H}$ 3.30 and 3.50/ $\delta_{\rm C}$ 62.3) groups were observed in **3** instead of those of an ethyl (1'; $\delta_{\rm H}$ 1.64 and 1.70/ $\delta_{\rm C}$ 25.8, 2'; $\delta_{\rm H}$ 1.03/ $\delta_{\rm C}$ 11.9) together with a secondary methyl (8-Me; $\delta_{\rm H}$ 1.06/ $\delta_{\rm C}$ 15.5) in 7. In the COSY correlations and HMBC correlations, the conectivity of the *n*-propyl group at C-4 (from H₂-1' to C-4, from H₂-2' to C-4 and from H-4 to C-1' and C-2') and a hydroxymethyl group at C-8 (from H₂-8 to C-7 and C-9, and from H-9 to CH₂-8) in 3 was confirmed (Supplementary Figure S2). In addition, the presence of an enol-type hydroxy group at C-3 was detected by the HMBC correlations from 3-OH ($\delta_{\rm H}$ br. 9.55–9.83 in DMSO-d₆, Supplementary Figure S7) to C-2 and C-4. Therefore, the planar structure of 3 was elucidated as shown in Figure 3, and it was designated as mangromicin D, a 8-oxymethylene-9-dehydroxy analog of mangromicin A (1).

Structure elucidation of mangromicin E (4)

Mangromicin E (**4**) was obtained as a pale yellow powder determined to have the molecular formula of $C_{22}H_{32}O_6$ by HRESIMS $[M + H]^+$ *m/z* 393.2277 (calcd for $C_{22}H_{33}O_6$, 393.2277). The 1D and 2D NMR spectra of **4** were obtained in CD₃OD.

The Journal of Antibiotics

From a comparison of the ¹H and ¹³C NMR of 4 and 7, the signals of one sp³ methine (2-CH; $\delta_{\rm H}$ 4.63/ $\delta_{\rm C}$ 55.2), one carbonyl carbon (C-2; δ_c 203.6), two olefinic carbons (C-8; δ_c 136.7 and C-9; 148.0), one sp^2 methine (9-CH; $\delta_{\rm H}$ 6.71) and a *n*-propyl (1'; $\delta_{\rm H}$ 1.32 and $1.97/\delta_{\rm C}$ 28.5, 2'; $\delta_{\rm H}$ 1.38 and 1.48/ $\delta_{\rm C}$ 21.1, 3'; $\delta_{\rm H}$ 0.98/ $\delta_{\rm C}$ 14.3) group were observed in 4 instead of those of two olefinic carbons (C-2 and C-3; δ_c 102.8 and 169.3), a methine (8-CH; δ_H 2.72/ δ_C 49.3), a methylene (H₂-9; $\delta_{\rm H}$ 1.76 and 37.7) and an ethyl (1'; $\delta_{\rm H}$ 1.64 and $1.70/\delta_{\rm C}$ 25.8, 2'; $\delta_{\rm H}$ 1.03/ $\delta_{\rm C}$ 11.9) group in 7. In the COSY correlations and HMBC correlations, the conectivity of the *n*-propyl group at C-4 (from H₂-1' to C-3, C-4 and C-5, from H₂-2' to C-4 and from H-4 to C-1' and C-2') in 4 was confirmed (Supplementary Figure S2). Therefore, the planar structure of 4 was elucidated as shown in Figure 3, and it was designated as mangromicin E, a 3-keto analog of mangromicin B (2). It is likely that akaerolide and mangromicin E are in relationship of stereoisomers.¹³

Structure elucidation of mangromicin F (5)

Mangromicin F (5) was obtained as a pale yellow powder determined to have the molecular formula of $C_{21}H_{32}O_7$ by HRESIMS $[M + H]^+$ *m/z* 397.2226 (calcd for $C_{21}H_{33}O_7$, 397.2218). The 1D and 2D NMR spectra of 5 were obtained in CD₃OD.

Table 3 ¹³C NMR data for mangromicin analogs

Position	D (3)ª	<i>E (4)</i> ^b	F (5) ^b	<i>G (6)</i> ^b	Н (7) ^ь	<i>l (8)</i> ^b
	δ _C , mult	δ _C , mult	δ _C , mult	δ _C , mult	δ _C , mult	δ _C , mult
1	164.4 C	172.2 C	169.2 C	169.0 C	169.6 C	168.3 C
2	101.8 C	55.2 CH	103.3 C	103.0 C	102.8 C	103.4 C
3	163.6 C	204.3 C	167.5 C	167.9 C	169.3 C	169.3 C
4	41.4 CH	50.9 CH	45.4 CH	44.2 CH	46.1 CH	45.6 CH
5	71.2 CH	77.8 CH	73.6 CH	73.9 CH	73.7 CH	73.8 CH
6	45.5 CH_2	38.4 CH ₂	46.6 CH ₂	44.0 CH ₂	44.3 CH ₂	44.0 CH ₂
7	210.1 C	203.6 C	213.7 C	212.4 C	212.8 C	197.7 C
8	49.2 CH	136.7 C	49.9 CH	43.6 CH	49.3 CH	147.5 C
9	33 CH ₂	148.0 CH	35.1 CH ₂	38.6 CH ₂	37.7 CH ₂	82.3 CH
10	66.3 CH	69.1 CH	68.9 CH	69.2 CH	69.2 CH	79.5 CH
11	81.2 CH	83.3 CH	84.6 CH	82.1 CH	82.0 CH	80.1 CH
12	35.0 CH	37.6 CH	37.2 CH	36.9 CH	37.0 CH	37.5 CH
13	47.9 CH ₂	50.5 CH ₂	49.7 CH ₂	$41.8\ \text{CH}_2$	$49.4\ CH_2$	48.0 CH ₂
14	81.2 C	83.5 C	83.2 C	87.0 C	83.8 C	85.0 C
15	$34.4 \ \text{CH}_2$	33.2 CH ₂	36.0 CH ₂	$34.2 \ \text{CH}_2$	$36.5 \ \text{CH}_2$	37.3 CH ₂
16	$18.1 \ \text{CH}_2$	$21.4 \ \text{CH}_2$	$19.5 \ \text{CH}_2$	$18.9 \ \text{CH}_2$	$19.5 \ \text{CH}_2$	19.4 CH ₂
1′	32.9 CH ₂	$28.5 \ \text{CH}_2$	$24.8 \ \text{CH}_2$	$34.2 \ \text{CH}_2$	$25.8\ CH_2$	25.7 CH ₂
2′	$19.1 \ \text{CH}_2$	$21.1 \ \text{CH}_2$	$21.1 \ \text{CH}_2$	$21.3 \ \text{CH}_2$		
2'-Me					$11.9 \ \text{CH}_3$	11.8 CH ₃
3'-Me	13.3 CH ₃	14.3 CH ₃	14.3 CH ₃	14.2 CH_3		
8-CH ₂	62.3 CH ₂					126.6 CH ₂
8-Me		11.8 CH_3	11.8 CH_3	15.3 CH_3	$15.5 \ \text{CH}_3$	
9-0Me						57.0 CH ₃
12-Me	14.6 CH_3	18.8 CH_3	18.7 CH_3	13.7 CH_3	15.5 CH_3	13.7 CH ₃
$14-CH_2$				65.9 CH ₂		
14-Me	$24.0 \; \text{CH}_3$	$25.5 \ \text{CH}_3$	$25.5 \ \text{CH}_3$		$25.3 \ \text{CH}_3$	24.5 CH ₃

^aIn DMSO-*d*₆ (80 °C). ^bIn CH₃OD.

From a comparison of the ¹H and ¹³C NMR of **5** and **7**, the signals of a hydroxymethyl (8-CH₂; $\delta_{\rm H}$ 3.52 and 3.67/ $\delta_{\rm C}$ 64.8) group were observed in **5** instead of those of a secondary methyl (8-Me; $\delta_{\rm H}$ 1.06/ $\delta_{\rm C}$ 15.5) in **7**. In the COSY correlations and HMBC correlations, the conectivity of a hydroxymethyl group at C-8 (from H₂-8 to C-7) in **5** was confirmed (Supplementary Figure S2). Therefore, the planar structure of **5** was elucidated as shown in Figure 3, and it was designated as mangromicin F, an 8-oxymethylene analog of mangromicin H (7).

Structure elucidation of mangromicin G (6)

Mangromicin G (6) was obtained as a pale yellow powder determined to have the molecular formula of $C_{22}H_{34}O_7$ by HRESIMS $[M + H]^+$ *m/z* 411.2385 (calcd for $C_{21}H_{35}O_7$, 411.2375). The 1D and 2D NMR spectra of **6** were obtained in CD₃OD.

From a comparison of the ¹H and ¹³C NMR of **6** and **7**, the signals of a *n*-propyl (1'; $\delta_{\rm H}$ 1.61 and 1.57/ $\delta_{\rm C}$ 34.2, 2'; $\delta_{\rm H}$ 1.38 and 1.53/ $\delta_{\rm C}$ 21.3, 3'; $\delta_{\rm H}$ 0.96/ $\delta_{\rm C}$ 14.2) and a hydroxymethyl (14-CH₂; $\delta_{\rm H}$ 3.47 and 3.96/ $\delta_{\rm C}$ 65.9) group were observed in **6** instead of those of an ethyl (1'; $\delta_{\rm H}$ 1.64 and 1.70/ $\delta_{\rm C}$ 25.8, 2'; $\delta_{\rm H}$ 1.03/ $\delta_{\rm C}$ 11.9) and a tertiary methyl (14-Me; $\delta_{\rm H}$ 1.34/ $\delta_{\rm C}$ 25.3) observed in **7**. In the COSY correlations and HMBC correlations, the connectivity of an *n*-propyl group at C-4 (from H₂-1' to C-3, C-4, C-5 and C-2', from H-4 to C-3 and C-5 and from H-5 to C-4 and C-1') and a hydroxymethyl group at C-14 (from H₂-8 to C-13, C-14 and C-15, and from H-13 and H-15 to CH₂-8) in **5** was confirmed (Supplementary Figure S2). Therefore, the planar structure of **6** was elucidated as shown in Figure 3, and it was designated as mangromicin G, a 4-de-ethyl-4-*n*-propyl-14-oxymethylene of mangromicin H (7).



Figure 2 Structure of mangromicin H (a) ${}^{1}H{}^{-1}H$ COSY and HOHAHA correlations (bold) and selected HMBC correlations (arrow) of mangromicin H (7). (b) Key ROESY and NOE correlations (line) and coupling constants (dot) of mangromicin H (7). (c) Probable configurations around H_{β1}-C4-C5-H_{α1} and H_{α2}-C10-C11-H_{β2} are indicated in Newman projections.

Structure elucidation of mangromicin I (8)

Mangromicin I (8) was obtained as a pale yellow powder determined to have the molecular formula of $C_{22}H_{32}O_7$ by HRESIMS $[M + H]^+$ *m/z* 409.2226 (calcd for $C_{22}H_{33}O_7$, 409.2222). The 1D and 2D NMR spectra of 7 were obtained in CD₃OD.

From a comparison of the ¹H and ¹³C NMR of **8** and **7**, the signals of a methylene (8-CH₂; $\delta_{\rm H}$ 5.68 and 6.48/ $\delta_{\rm C}$ 126.6), one methine (9-CH; $\delta_{\rm H}$ 4.20/ $\delta_{\rm C}$ 82.3) and methoxy (9-OCH₃; $\delta_{\rm H}$ 3.24/ $\delta_{\rm C}$ 57.0) group were observed in **8**, instead of those of a secondary methyl (8-Me; $\delta_{\rm H}$ 1.06/ $\delta_{\rm C}$ 15.5) and a methylene (H₂-9; $\delta_{\rm H}$ 1.76 and 37.7) observed in **7**. In the COSY correlations and HMBC correlations, the conectivity of an exomethylene group at C-8 (from H₂-8 to C-7, C-8 and C-9 and from H-9 to H₂-8) in **8** was confirmed (Supplementary Figure S2). Therefore, the planar structure of **8** was elucidated as shown in Figure 3, and it was designated as mangromicin I, an 8-de-methyl-8-exomethylene-9-demethylene-9-methoxy analog of mangromicin H (7).

Biological activities of mangromicins

Eight mangromicin analogs were evaluated in a panel of assays, such as antimicrobial activities for pathogenic bacteria and fungi, antivirus activity, cytotoxicity for cancer cells and antiparasitic activity for parasitic protozoa. In consequence, all mangromicin analogs except for mangromicin E (4) and I (8) had more potent scavenging activity against 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radicals than that of α -tocopherol. Among the eight compounds, mangromicin A (1) showed the most potent anti-oxidant activity s (IC₅₀ = 2.4 μ M, Table 4, Supplementary Figure 3S).



Mangromicin	R₁	R ₂	R ₃	R₄
D (3)	-CH ₂ CH ₂ CH ₃	-CH ₂ OH	-H	-CH ₃
F (5)	-C ₂ H ₅	-CH ₂ OH	-H	-CH ₃
G (6)	-CH ₂ CH ₂ CH ₃	-CH ₃	-H	-CH ₂ OH
H (7)	-C ₂ H ₅	-CH ₃	-H	-CH ₃
l (8)	$-C_2H_5$	=CH ₂	-OCH₃	-CH ₃
· · · ·				

Figure 3 Structures of mangromicins D (3), E (4), F (5), G (6), H (7) and I (8).



	DPPH free radical		
Compound	scavenging activity (IC ₅₀ , µм)		
Mangromicin A	2.4 ± 0.10		
Mangromicin B	3.8±0.03		
Mangromicin D	3.1 ± 0.01		
Mangromicin E	31.1±0.33		
Mangromicin F	3.9 ± 0.05		
Mangromicin G	6.5 ± 0.05		
Mangromicin H	4.1 ± 0.04		
Mangromicin I	16.3 ± 0.15		
α-tocopherol	11.4 ± 0.77		

In addition, mangromicin analogs were investigated for scavenging activity with respect to nitric oxygen (NO) generated from LPSstimulated RAW264.7 cells, a murine macrophage cell line. All mangromicin analogs (at final concentration of 100 µM) showed no cytotoxic activity against RAW264.7 cells (data not shown). As shown in Figure 4, mangromicin I (7) had the most potent NO scavenging activity. To further understand the effect of mangromicin B (2), which was the second-most potent analog, on the mRNA expression profiles of iNOS in murine macrophage RAW264.7 cells, RT-PCR (reverse transcription-polymerase chain reaction) tests were conducted. As mangromicin I (8) was in short supply, mangromicin B (2) was used for the RT-PCR experiment. Mangromicin B (2) did not attenuate mRNA expression levels of iNOS when compared with LPS-stimulated cells (Supplementary Figure S4). It was therefore suggested that mangromicin B (2) has an ability to scavenge NO generated from LPS-stimulated RAW264.7 cells.

Interestingly, the anti-oxidant activity of mangromicin E (4) was reduced about 10 times than that of mangromicin B (2). As mangromicin E (4) had a carbonyl group at the C-3 position instead of hydroxy group of mangromicin B (2), it was suggested that the hydroxy group at the C-3 position is important in the scavenging activity for DPPH free radicals. Conversely, mangromicins B (2), E (4) and I (8) showed more potent NO scavenging activity among the analogs tested. As these three analogs had an α , β -unsaturated ketone carbonyl group at the C-7 position, it was suggested that this common partial structure is important in the NO scavenging activity.



CH₃

ĊΗ₃

ÓН

CH₃

Mangromicin E (4)

Figure 4 Scavenging effects of mangromicin analogs on NO generated from LPS-stimulated a murine macrophage RAW264.7 cell line.

Thus, there was poor correlation between DPPH free radical scavenging activity and NO scavenging activity in mangromicin analogs. Therefore, the functional site for radical scavenging activity in mangromicin analogs may be different according to radical species.

METHODS

H₃C

General experimental procedures

NMR spectra were measured using an Agilent Technologies NMR System 400 and INOVA 600 (Varian Co., Palo Alto, CA, USA) or JEOL JNM-ECA 500 spectrometer (JEOL Ltd., Tokyo, Japan), with ¹H-NMR at 400, 500 or 600 MHz and ¹³C-NMR at 100, 125 or 150 MHz in CD₃OD or DMSO- d_6 . The chemical shifts are expressed in p.p.m. and are referenced to residual CD₃OD (3.31 p.p.m.) or DMSO- d_6 (2.48 p.p.m.) in the ¹H-NMR spectra and CD₃OD (49 p.p.m.) or DMSO- d_6 (39.5 p.p.m.) in the ¹³C-NMR spectra. LC-ESI-MS spectra were measured using an AB Sciex QSTAR Hybrid LC/MS/MS Systems (AB Sciex, Framingham, MA, USA). IR spectra (KBr) were taken on a Horiba FT-710 Fourier transform IR spectrometer (Horiba Ltd, Kyoto, Japan). UV spectra were measured with a Hitachi U-2810 spectrophotometer (Hitachi High-Technologies Co., Tokyo, Japan). Optical rotation was measured on a JASCO model DIP-1000 polarimeter (Jasco Co., Tokyo, Japan). Fluorescence was monitored using a Corona Grating Microplate Reader SH-9000 Lab (Corona Electric Co., Ltd., Ibaraki, Japan).

Reagents

Reagents were purchased from the following sources: LPS was purchased from Sigma-Aldrich Co. (St Louis, MO, USA). DPPH, IFN-γ and NG-monomethyl-

L-arginine were purchased from Wako Pure Chemical Industries Ltd. (Osaka, Japan). Diaminofluorescein-2 (DAF-2) was purchased from Sekisui Medical Co., Ltd. (Tokyo, Japan). All other reagents used were of analytical grade.

Fermentation

The strain K10-0216 was grown and maintained on agar slants consisting of 1.0% starch, 0.3% NZ amine, 0.1% yeast extract, 0.1% meat extract, 1.2% agar and 0.3% CaCO₃. A loop of spores of strain K10-0216 was inoculated into 100 ml of seed medium, consisting of 2.4% starch, 0.1% glucose, 0.3% peptone, 0.3% meat extract, 0.5% yeast extract and 0.4% CaCO₃ (adjusted to pH 7.0 before sterilization) in a 500-ml Erlenmeyer flask. The flask was incubated on a rotary shaker (210 r.p.m.) at 27 °C for 3 days. A 1-ml portion of the seed culture was transferred to 500-ml Erlenmeyer flasks (total 150) containing 100 ml of starch medium, consisting of 5.0% soluble starch, 0.5% glycerol, 1.0% de-fatted wheat germ, 1.0% dry yeast and 0.3% CaCO₃ (adjusted to pH 7.0 before sterilization) and fermentation was carried out on a rotary shaker (210 r.p.m.) at 27 °C for 7 days.

Biological activities of mangromicins

Effect of mangromicins on DPPH free radicals: antioxidative activity was estimated by the DPPH free radical scavenging method, as described previously with a minor modification.¹⁴ DPPH was dissolved in dimethylformamide (10 mg ml⁻¹) and then diluted to 120 μ moll⁻¹ with 0.1 moll⁻¹ Tris-HCl buffer (pH 7.6) containing 5% Triton X-100. Ten microliters of the sample solution was then added to 90 μ l of a DPPH solution. After incubation for 30 min in the dark at room temperature, the absorbance at 517 nm was measured with a microplate reader (Corona Electric).

Effect of mangromicins on NO production generated from LPS-stimulated RAW 264.7 cells: RAW 264.7 cells (a mouse macrophage cell line) were obtained from the American Type Culture Collection (Rockville, MD, USA). Raw 264.7 cells were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, streptomycin (100 Um)⁻¹) and penicillin G (100 Um)⁻¹) at 37 °C in an atmosphere of 5% CO₂ and 95% air, as described previously.¹⁵

RAW 264.7 cells were plated in wells of a 96-well microplate $(1 \times 10^5$ cells/ well), and were cultured for 6 h to make macrophages adherent. Cells were subsequently cultured for 16 h with 200 µl of fresh medium containing LPS (100 ng ml^{-1}) and IFN- γ (10 Uml^{-1}) . The activated cells adherent in wells were washed twice with KRP (Krebs–Ringer–Phosphate) buffer, 200 µl of medium containing each mangromicin analog (a final concentration at $100 \,\mu\text{mol}\,1^{-1}$) diluted in DMSO with 1 mM L-arginine and 10 µM DAF-2 was added to each well. DAF-2, a sensitive fluorescent indicator, was used for the detection of NO.^{16,17} The final DMSO concentration was <0.1%. At this concentration, DMSO did not show any NO-induction without stimulation with LPS. After incubation for 2 h, the supernatants were transferred to black microplates and the florescence was measured with a microplate reader (Corona Electric) calibrated for excitation at 495 nm and emission at 515 nm.

ACKNOWLEDGEMENTS

This study was supported, in part, by funds from Quality Assurance Framework of Higher Education from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan, and the Institute for Fermentation (IFO), Osaka, Japan. We are grateful to Ms Noriko Sato and Dr Kenichiro Nagai, School of Pharmacy, Kitasato University, for measurements of NMR and MS spectra and Ms Megumi Niitsuma, Kitasato Institute for Life Sciences, Kitasato University, for RT-PCR measurements.

- Newman, D. J. & Gordon, M. C. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod. 75, 311–335 (2012).
- 2 Ghisalberti, E. L. Detection and isolation of bioactive natural products. *Bioactive Natural Products* (Eds Molyneux, R. J. & Colegate, S. M.) 11–76 (CRC Press, Boca Raton, FL, 2007).
- 3 Umezawa, H. et al. Production and isolation of a new antibiotic: kanamycin. J. Antibiot. 10, 181–188 (1957).
- 4 Hata, T. et al. Leucomycin, a new antibiotic. J. Antibiot. 6, 87-89 (1953).
- 5 Burg, R. W. et al. Avermectins, new family of potent anthelmintic agents: producing organism and fermentation. Antimicrob. Agents Chemother. 15, 361–367 (1979).
- 6 Nakashima, T. *et al.* Trehangelins A, B and C, novel photo-oxidative hemolysis inhibitors produced by an endophytic actinomycete, *Polymorphospora rubra* K07-0510. *J. Antibiot.* **66**, 311–317 (2013).
- 7 Nakashima, T. et al. Mangromicins A and B: structure and anti-trypanosomal activity of two new cyclopentadecane compounds from *Lechevalieria aerocolonigenes* K10-0216. J. Antibiot. 67, 253–260 (2013).
- 8 Ōmura, S. *et al.* A new alkaloid AM-2282 OF *Streptomyces* origin. Taxonomy, fermentation, isolation and preliminary characterization. *J. Antibiot.* **30**, 275–282 (1977).
- 9 Omura, S. et al. A new antibiotic, AM-2504. Agric. Biol. Chem. 41, 1827–1828 (1977).
- 10 Ōmura, S. et al. Novel mangromycin compound and production method therefor. Japan Patent 2011-191404 (2011).
- 11 Ōmura, S. et al. Novel mangromycin compound and production method therefor. WO 2013031239 (2013).
- 12 Kamiya, Y. et al. Structural analysis and biological activities of mangromicin analogs. Abstracts of Papers of the 28th Annual Meeting of the Society for Actinomycetes Japan 0-21 (The society for Actinomycetes Japan, Hiroshima, Japan, 2013).
- 13 Igarashi, Y. et al. Akaeolide, a carbocyclic polyketide from marine-derived Streptomyces. Org. Lett. 15, 5678–5681 (2013).
- 14 Nakashima, T. et al. Inhibitory or scavenging action of ketoconazole and ciclopiroxolamine against reactive oxygen species released by primed inflammatory cells. Br. J. Dermatol. 156, 720–727 (2007).
- 15 Nakashima, T., Kurachi, M., Kato, Y., Yamaguchi, K. & Oda, T. Characterization of bacterium isolated from the sediment at coastal area of Omura Bay in Japan and several biological activities of pigment produced by this isolate. *Microbiol. Immunol.* 49, 407–415 (2005).
- 16 Kojima, H. et al. Development of a fluorescent indicator for nitric oxide based on the fluorescein chromophore. Chem. Pharm. Bull. 46, 373–375 (1998).
- 17 Nakatsubo, N. *et al.* Direct evidence of nitric oxide production from bovine aortic endothelial cells using new fluorescence indicators: diaminofluoresceins. *FEBS Lett.* 427, 263–266 (1998).

Supplementary Information accompanies the paper on The Journal of Antibiotics website (http://www.nature.com/ja)